<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557984</url>
  </required_header>
  <id_info>
    <org_study_id>SNS_Study_01</org_study_id>
    <nct_id>NCT02557984</nct_id>
  </id_info>
  <brief_title>Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity</brief_title>
  <official_title>Dopamine D2/3- and μ-opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how the dopamine and opioid system is involved in
      reward processing, specifically in cue-induced reward responding and reward impulsivity,
      using dopamine and opioid receptor antagonists in healthy participants. The investigators
      predict that particularly the dopamine challenge should alter cue-induced reward responding
      and reward impulsivity. Such effects would be of high interest for the treatment of disorders
      which involve impairments of reward processing such as addiction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators use amisulpride and naltrexone to elucidate what function the
      dopamine and opioid system have in the processing of reward. Amisulpride [Solian®;
      sanofi-aventis] is an atypical antipsychotic and acts as an antagonist at dopamine D2 and D3
      (D2/D3) receptors with very high specificity. Amisulpride has been used in numerous past
      studies to study the role of dopamine in the brain, for example in studies on reinforcement
      learning, memory, and attentional bias in stimulant dependence. Naltrexone [Naltrexin®; OrPha
      Swiss GmbH] is an opioid antagonist and is clinically used in the management of alcohol and
      opioid dependence. It has been used to investigate the role of opioid in pain perception,
      taste detection and recognition, and smoking behavior. The investigators were interested in
      particular how amisulpride and naltrexone influence cue-induced reward responding and reward
      impulsivity.

      Study Aims

      A) Investigating the role of the dopamine system in cue-induced reward responding; B)
      Investigating the role of the dopamine system in reward impulsivity; C) Investigating the
      role of the opioid system in cue-induced reward responding; A) Investigating the role of the
      opioid system in reward impulsivity.

      Study Design

      This is a double-blind, randomized, placebo-controlled, between-subject blocker study. 121
      participants received either placebo, the dopamine D2/D3 receptor antagonist amisulpride (400
      mg), or the unselective opioid receptor antagonist naltrexone (50 mg), 3h before the
      experimental tasks. Subjective effects on mood were assessed by visual analogue scales (VAS).
      Cue-induced reward responding was measured using a standard Pavlovian-to-Instrumental
      Transfer (PIT) task, where participants press a button for reward in the presence of a
      stimulus predicting that reward. Reward impulsivity was measured using a Delay Discounting
      (DD) Task, in which participants choose between smaller, immediate rewards and larger,
      delayed rewards.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cue-Induced Reward Responding Measure</measure>
    <time_frame>1 day</time_frame>
    <description>Measured using a Pavlovian-to-Instrumental Transfer Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reward Impulsivity Measure</measure>
    <time_frame>1 day</time_frame>
    <description>Measured using a Delay Discounting Task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>1 day</time_frame>
    <description>Current Mood assessed by Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Addiction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Amisulpride (Solian®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Naltrexone (Naltrexin®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Pill</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactose Placebo Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>400 mg Amisulpride</description>
    <arm_group_label>Amisulpride</arm_group_label>
    <other_name>Solian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>50 mg Naltrexone</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Naltrexin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically and psychiatrically healthy men and women

        Exclusion Criteria:

          -  Serious past brain disease or injury

          -  Pacemaker or neurostimulator

          -  Hearing aid

          -  Surgery to head or heart

          -  Potential metal parts in body (metal splinters, gun wounds, shrapnel or surgical
             clips)

          -  Neurological or psychiatric problems (including alcoholism, depression, schizophrenia,
             bipolar disorders, anxiety disorder, claustrophobia, or parkinsonian symptoms)

          -  High blood pressure, low blood pressure, cardiac attack in anamnesis, irregular heart
             rate

          -  Epilepsy

          -  Emphysema, chest problems, or multiple sclerosis

          -  Respiratory problems (including difficulty breathing through the nose)

          -  Pregnancy, nursing, or planning pregnancy

          -  Diabetes

          -  Acute Hepatitis

          -  Allergy or sensitivity to lactose

          -  Allergy or sensitivity to amisulpride or naltrexone

          -  Breast cancer or current tumors

          -  Insufficiency of liver or kidney

          -  Past use of opiates or other drugs that may interact with amisulpride or naltrexone
             (such as stimulants)

          -  Currently taking medications known to interact with amisulpride or naltrexone
             (including medicines used to treat irregular heart rhythm such as quinidine,
             disopyramide, amiodarone and sotalol, cisapride, antibiotics such as erythromycin and
             pentamidine, levodopa, thioridazone (an antipsychotic), or methadone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris B Quednow, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Psychiatry Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe N Tobler, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Arbisi PA, Billington CJ, Levine AS. The effect of naltrexone on taste detection and recognition threshold. Appetite. 1999 Apr;32(2):241-9.</citation>
    <PMID>10097028</PMID>
  </reference>
  <reference>
    <citation>Gibbs AA, Naudts KH, Spencer EP, David AS. The role of dopamine in attentional and memory biases for emotional information. Am J Psychiatry. 2007 Oct;164(10):1603-9; quiz 1624.</citation>
    <PMID>17898353</PMID>
  </reference>
  <reference>
    <citation>Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988 Mar;35(3):192-213. Review.</citation>
    <PMID>2836152</PMID>
  </reference>
  <reference>
    <citation>Jocham G, Klein TA, Ullsperger M. Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices. J Neurosci. 2011 Feb 2;31(5):1606-13. doi: 10.1523/JNEUROSCI.3904-10.2011.</citation>
    <PMID>21289169</PMID>
  </reference>
  <reference>
    <citation>Ersche KD, Bullmore ET, Craig KJ, Shabbir SS, Abbott S, Müller U, Ooi C, Suckling J, Barnes A, Sahakian BJ, Merlo-Pich EV, Robbins TW. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry. 2010 Jun;67(6):632-44. doi: 10.1001/archgenpsychiatry.2010.60.</citation>
    <PMID>20530013</PMID>
  </reference>
  <reference>
    <citation>Morein-Zamir S, Craig KJ, Ersche KD, Abbott S, Muller U, Fineberg NA, Bullmore ET, Sahakian BJ, Robbins TW. Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation. Psychopharmacology (Berl). 2010 Oct;212(3):357-67. doi: 10.1007/s00213-010-1963-z. Epub 2010 Jul 27.</citation>
    <PMID>20661550</PMID>
  </reference>
  <reference>
    <citation>Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl). 2005 Jun;180(1):41-8. Epub 2005 Jan 29.</citation>
    <PMID>15682300</PMID>
  </reference>
  <reference>
    <citation>Lovibond PF, Colagiuri B. Facilitation of voluntary goal-directed action by reward cues. Psychol Sci. 2013 Oct;24(10):2030-7. doi: 10.1177/0956797613484043. Epub 2013 Aug 27.</citation>
    <PMID>23982242</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dopamine</keyword>
  <keyword>Opioid</keyword>
  <keyword>Reward</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impulsive Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Narcotic Antagonists</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

